Global Myelodysplastic Syndrome Treatment Market, by Drug (Lenalidomide, Decitabine, Azacitidine, and Phase 3 Drugs), by Route of Administration (Injection and Oral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 3,265.6 Million in 2022 and is expected to exhibit a CAGR of 9.3% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Increasing research and development for the novel drug therapy used in the treatment of Myelodysplastic Syndrome is expected to drive the market growth over the forecast period. For instance, in December 2021, OncLive Peer Exchange, an organization panel of hematologic cancer experts shared their insights on the most recent the US Food and Drug Administration-approved agents for Myelodysplastic Syndrome, including luspatercept and decitabine/cedazuridine (Inqovi), both of which were approved in 2020. More recently, several agents for specific patient subgroups have been approved by the US Food and Drug Administration, including for patients with very low-risk to high-risk MDS, and many other novel agents with unique mechanisms of action are on the horizon.
Moreover, in April 2020, the U.S. Food and Drug Administration (FDA) approved Reblozyl (luspatercept-aamt), the first and only Erythroid Maturation Agent, to treat anemia in adults with Lower-Risk Myelodysplastic Syndromes (MDS).
Global Myelodysplastic Syndrome Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.
However, the COVID-19 pandemic had a negative impact on the global myelodysplastic syndrome treatment market, owing to decrease in the supply of the drugs used in the treatment of Myelodysplastic Syndrome. For instance, in July 2020, according to the National Center for Biotechnology Information, the impact of the measures implemented to address the COVID-19 pandemic appear to have been most homogenous to date at the very end of the drug supply chain, in the destination markets. The overall impact on bulk supply is reportedly more heterogenous, both across drugs and across countries. Increased controls resulting from the implementation of measures to fight the spread of COVID-19 have had double-edged consequences on large-scale drug supply. There have also been reports of organized criminal groups involved in drug trafficking becoming distracted from their usual illicit activities by emerging crime linked to the COVID-19 pandemic; for example, cybercrime and trafficking in falsified medicines in the Balkan countries.
Global Myelodysplastic Syndrome Treatment Market: Key Developments
In May 2021, Novartis, a pharmaceutical company, received the U.S. Food and Drug Administration (FDA) fast track designation for sabatolimab (MBG453) for the treatment of adult patients with myelodysplastic syndromes (MDS) defined with an IPSS-R risk category of high or very high risk in combination with hypomethylating agents. Fast track designation facilitates the development and expedites the review of drugs to treat serious conditions and fulfill unmet medical needs. Sabatolimab is a first-in-class investigational immuno-myeloid therapy that binds to TIM-3, a novel target expressed on multiple immune cell types and leukemic cells and blasts, but not on the normal stem cells that induce blood formation. It is in development for Myelodysplastic syndromes and acute myeloid leukemia (AML).